Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

There are a few additional p53 activating drugs in the pipeline in addition to APR-246 and kevetrin:

COTI-2 reactivates mutant p53, also has additional p53 independent mechanisms of action

Currently in Phase I

http://criticaloutcome.com/wp-content/uploads/2016/05/Oncotarget2016.pdf

(Critical Outcomes technology is in poor shape financially, with limited assets to develop their drugs).


PK11007 reactivates mutant p53

http://www.pnas.org/content/113/36/E5271

http://www.sciencedirect.com/science/article/pii/S0304383517306225

Still preclinical / in academic labs.


A nice overview of drugs that re-activate mutant p53:

http://www.sciencedirect.com/science/article/pii/S0959804917310742